LOGIN  |  REGISTER
Amneal Pharmaceuticals
Astria Therapeutics

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

October 23, 2024 | Last Trade: US$1.71 0.01 0.59

SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XVII Conference in Los Angeles on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET).

LD Micro Main Event XVII Conference
Presentation Date: Wednesday, October 30, 2024
Presentation Time: 2:00 p.m. PT (5:00 p.m. ET)
Webcast: Click here

Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro representative or email This email address is being protected from spambots. You need JavaScript enabled to view it..

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Matt Steinberg
FINN Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page